In another phase I/II clinical trial, Wittig and colleagues cotransfected IL-7 and granulocyte-macrophage colony-stimulating factor (GM-CSF) genes in autologous tumor cells as a therapeutic vaccine to immunize patients with progressive metastatic carcinoma (90). The gene discussed is CSF2; the disease is neoplasm.